Therapeutic Hypothermia in Neonatal Hypoxic-Ischemic Encephalopathy

Curr Neurol Neurosci Rep. 2019 Jan 14;19(2):2. doi: 10.1007/s11910-019-0916-0.

Abstract

Purpose of review: Therapeutic hypothermia reduces death or disability in term and near-term infants with moderate-severe hypoxic-ischemic encephalopathy. Nevertheless, many infants still survive with disability, despite hypothermia, supporting further research in to ways to further improve neurologic outcomes.

Recent findings: Recent clinical and experimental studies have refined our understanding of the key parameters for hypothermic neuroprotection, including timing of initiation, depth, and duration of hypothermia, and subsequent rewarming rate. However, important knowledge gaps remain. There is encouraging clinical evidence from a small phase II trial that combined treatment of hypothermia with recombinant erythropoietin further reduces risk of disability but definitive studies are still needed. In conclusion, recent studies suggest that current protocols for therapeutic hypothermia are near-optimal, and that the key to better neurodevelopmental outcomes is earlier diagnosis and initiation of hypothermia after birth. Further research is essential to find and evaluate ways to further improve outcomes after hypoxic-ischemic encephalopathy, including add-on therapies for therapeutic hypothermia and preventing pyrexia during labor and delivery.

Keywords: Erythropoietin; Fetal sheep; Neonatal encephalopathy; Neonatal examination; Neonatal neuroprotection; Therapeutic hypothermia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Hypothermia, Induced / methods*
  • Hypoxia-Ischemia, Brain / physiopathology*
  • Infant
  • Infant, Newborn
  • Neuroprotection